Literature DB >> 31410842

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

Hamza Hashmi1,2, Christina Bachmeier1, Julio C Chavez3,4, Jinming Song4,5, Mohammad Hussaini4,5, Gabriel Krivenko1, Taiga Nishihori1,4, Hiroshi Kotani6, Marco L Davila1,4, Frederick L Locke1,4, Michael D Jain1,4.   

Abstract

Entities:  

Keywords:  chimeric antigen receptor T cell therapy; cytokine release syndrome; haemophagocytic lymphohistiocytosis

Mesh：

Substances：

Year:  2019        PMID： 31410842     DOI： 10.1111/bjh.16155

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  14 in total

1.  Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Authors:  Cheng Zu; Kexin Wang; Qiqi Zhang; Yongxian Hu; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

Review 2.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 3.  Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.

Authors:  Cassie K Chou; Cameron J Turtle
Journal:  Expert Opin Biol Ther       Date:  2020-02-24       Impact factor: 4.388

4.  Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.

Authors:  Kazusa Ishii; Marie Pouzolles; Christopher D Chien; Rebecca A Erwin-Cohen; M Eric Kohler; Haiying Qin; Haiyan Lei; Skyler Kuhn; Amanda K Ombrello; Alina Dulau-Florea; Michael A Eckhaus; Haneen Shalabi; Bonnie Yates; Daniel A Lichtenstein; Valérie S Zimmermann; Taisuke Kondo; Jack F Shern; Howard A Young; Naomi Taylor; Nirali N Shah; Terry J Fry
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 5.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

Review 6.  Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:  Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah
Journal:  Nat Rev Clin Oncol       Date:  2021-01-25       Impact factor: 66.675

7.  Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.

Authors:  Daniel A Lichtenstein; Fiorella Schischlik; Lipei Shao; Seth M Steinberg; Bonnie Yates; Hao-Wei Wang; Yanyu Wang; Jon Inglefield; Alina Dulau-Florea; Francesco Ceppi; Leandro C Hermida; Kate Stringaris; Kim Dunham; Philip Homan; Parthav Jailwala; Justin Mirazee; Welles Robinson; Karen M Chisholm; Constance Yuan; Maryalice Stetler-Stevenson; Amanda K Ombrello; Jianjian Jin; Terry J Fry; Naomi Taylor; Steven L Highfill; Ping Jin; Rebecca A Gardner; Haneen Shalabi; Eytan Ruppin; David F Stroncek; Nirali N Shah
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

8.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Authors:  Loretta J Nastoupil; Michael D Jain; Lei Feng; Jay Y Spiegel; Armin Ghobadi; Yi Lin; Saurabh Dahiya; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Alison R Sehgal; Andre Goy; Brian T Hill; Khoan Vu; Charalambos Andreadis; Javier Munoz; Jason Westin; Julio C Chavez; Amanda Cashen; N Nora Bennani; Aaron P Rapoport; Julie M Vose; David B Miklos; Sattva S Neelapu; Frederick L Locke
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 50.717

9.  Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.

Authors:  Jennifer M Logue; Elisa Zucchetti; Christina A Bachmeier; Gabriel S Krivenko; Victoria Larson; Daniel Ninh; Giovanni Grillo; Biwei Cao; Jongphil Kim; Julio C Chavez; Aliyah Baluch; Farhad Khimani; Aleksandr Lazaryan; Taiga Nishihori; Hien D Liu; Javier Pinilla-Ibarz; Bijal D Shah; Rawan Faramand; Anna E Coghill; Marco L Davila; Bhagirathbhai R Dholaria; Michael D Jain; Frederick L Locke
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

10.  Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Authors:  Melissa R Hines; Camille Keenan; Gabriela Maron Alfaro; Cheng Cheng; Yinmei Zhou; Akshay Sharma; Caitlin Hurley; Kim E Nichols; Stephen Gottschalk; Brandon M Triplett; Aimee C Talleur
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.